RKDA vs LIN vs APD vs PGEN vs ALB

For growth investors, Linde plc (LIN) is the stronger pick with 3.

0% revenue growth year-over-year, versus -36. 9% for Precigen, Inc. (PGEN). Linde plc (LIN) offers the better valuation at 33. 8x trailing P/E (27. 7x forward), making it the more compelling value choice. Analysts rate Linde plc (LIN) a "Buy" — based on 28 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Albemarle Corporation is actually cheaper at 22.

4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Linde plc (LIN) delivered a total return of +73.

9%, compared to -98. 9% for Arcadia Biosciences, Inc. (RKDA). Over 10 years, the gap is even starker: LIN returned +375. 2% versus RKDA's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Linde plc (LIN) is the lower-risk stock at 0.

24β versus Albemarle Corporation's 1. 60β — meaning ALB is approximately 565% more volatile than LIN relative to the S&P 500. On balance sheet safety, Precigen, Inc. (PGEN) carries a lower debt/equity ratio of 14% versus 106% for Air Products and Chemicals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Linde plc (LIN) is pulling ahead at 3.

0% versus -36. 9% for Precigen, Inc. (PGEN). On earnings-per-share growth, the picture is similar: Arcadia Biosciences, Inc. grew EPS 66. 9% year-over-year, compared to -110. 3% for Air Products and Chemicals, Inc.. Over a 3-year CAGR, LIN leads at 0. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Linde plc (LIN) is the more profitable company, earning 20.

3% net margin versus -32. 2% for Precigen, Inc. — meaning it keeps 20. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LIN leads at 26. 3% versus -34. 4% for PGEN. At the gross margin level — before operating expenses — LIN leads at 43. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Albemarle Corporation (ALB) trades at 22.

4x forward P/E versus 27. 7x for Linde plc — 5. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PGEN: 44. 6% to $6. 00.

In this comparison, APD (2.

4% yield), LIN (1. 2% yield), ALB (0. 8% yield) pay a dividend. RKDA, PGEN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Linde plc (LIN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

24), 1. 2% yield, +375. 2% 10Y return). Both have compounded well over 10 years (LIN: +375. 2%, PGEN: -84. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RKDA (Basic Materials) and LIN (Basic Materials) and APD (Basic Materials) and PGEN (Healthcare) and ALB (Basic Materials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

LIN, APD, ALB pay a dividend while RKDA, PGEN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.